Albany - NY, Oct. 20, 2015 (GLOBE NEWSWIRE) -- According to a new market report published by Transparency Market Research "Organ Transplant Immunosuppressant Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2015 - 2023," the global organ transplant immunosuppressant drugs market was valued at US$5.1 bn in 2014 and is expected to decline at a CAGR of - (5.0)% from 2015 to 2023, to reach an estimated value of US$3.2 bn in 2023.
Browse Market Research Report on Organ Transplant Immunosuppressant Drugs Market:
The report provides detailed analysis of current and emerging immunosuppressant drugs administered during organ transplant, bifurcating them based on type of drug and transplant. Drugs have been analyzed by segments such as Calcineurin Inhibitors, Anti-proliferative Agents, mTOR Inhibitors, Antibodies, and Steroids. Among these, Calcineurin Inhibitors is the largest segment of the global organ transplant immunosuppressant drugs market. Rising preference for calcineurin inhibitors is due to its adequate immunosuppression properties coupled with lesser side effects in comparison to other immunosuppressant drugs. This factor could propel the market during the forecast period. The Calcineurin Inhibitors segment was valued at US$2.3 bn in 2014 and is likely to account for US$1.3 bn by 2023, declining at a CAGR of -(5.6) % from 2015 to 2023.
The antibodies segment is projected to attain the second highest CAGR during the forecast period, as increased number of organ transplant procedures would accelerate the drug discovery processes of antibodies. The antibodies and mTOR inhibitors drug segments held the third and fourth largest shares of the global market in terms of revenue in 2014. However, the overall immunosuppressant drugs market will witness negative growth due to the impact of side effects such as hyperglycemia, nephrotoxicity, and neurotoxicity. The market for immunosuppressive drugs is presently thriving on off-label drugs and therefore growth in this segment would require proven effectiveness of maintenance drugs with fewer side effects for organ transplant immunosuppression. This contraction in growth is expected to be nearly 5% and will be driven by launch of generic drugs due to patent loss.
Get Sample Report Copy of Organ Transplant Immunosuppressant Drugs Market:
The need of the hour is to have innovative, affordable immunosuppressant drugs along with milder and lesser post-drug therapy contraindications. The report offers a detailed analysis of factors responsible for the market growth and outlines a possible growth trajectory for other segments. The report is thus compiled with the prime intent of updating the stakeholders with the market dynamics which are graphically illustrated.
The organ transplant immunosuppressant drugs market has been divided into six segments based on transplant type: kidney, bone marrow, liver, heart, lung, and others (intestine and multivisceral transplants). Kidney transplantation is the most preferred treatment for end-stage renal disease (ESRD) and the segment was valued at US$2.7 bn in 2014 and is expected to account for US$1.7 mn by 2023, declining at a CAGR of -4.8% from 2015 to 2023. Higher number of organ transplant operations is expected to drive the growth of the segment in the near future. Patient non-adherence to immunosuppressive medications is related to high medication cost and inability to pay for expensive procedures. The cost of post-transplantation care and ongoing immunosuppression in several low and middle income countries are significant barriers to the development of higher transplantation capacity. This has been a driving factor for illegal organ trafficking rampant across the world, due to heightened demand for medical tourism in developing countries.
Allergan plc, AbbVie, Inc., Bristol-Myers Squibb, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Pfizer, Inc., Janssen Pharmaceuticals, Astellas Pharma, Inc, Veloxis Pharmaceuticals A/S, Novartis AG, and Sanofi S.A. are the major players operating in the organ transplant immunosuppressant drugs market globally. In 2014, Novartis AG and Astellas Pharma Inc were identified as the leading players of the global organ transplant immunosuppressant drugs market. Most of these players continuously innovate by developing new products and improvise existing ones to keep pace with technological advances in order to maintain their position in the global market.
The global organ transplant immunosuppressant drugs market is segmented as follows:
Global Organ Transplant Immunosuppressant Drugs, by Drug Class
- Mycophenolate Mofetil
- Mycophenolate Sodium
- Antithymocyte Globulin
Global Organ Transplant Immunosuppressant Drugs, by Transplant
- Bone Marrow
- Others (Intestinal and Multi-visceral Organs)
Global Organ Transplant Immunosuppressant Drugs, by Geography
- Rest of Europe
- Rest of Asia Pacific
- Rest of Latin America
Rest of the World
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company's exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
TMR's data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.
CONTACT: Mr. Nachiket Ghumare State Tower, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free: 866-552-3453 Email: firstname.lastname@example.org Website: http://www.transparencymarketresearch.com
Source:Transparency Market Research